Endocrinology – MedMeetings

Modelling the Legacy Effect of Glycaemic Exposure on Long-Term Cardiovascular Disease in Newly Diagnosed Type 2 Diabetes

This study was presented as part of the session “Diabetes and Heart Talk” on June 23rd, 2025, during the 85th ADA Scientific Sessions held in

Can We Improve the Quality of Weight Loss by Augmenting Fat Mass Loss while Preserving Lean Mass? The BELIEVE Study of Bimagrumab + Semaglutide

This study was presented on June 23rd, 2025, during the 85th ADA Scientific Sessions held in Chicago, IL. A groundbreaking obesity treatment combining two medications

The Relationship of Relative Fat Mass (RFM) to In Vivo Peripheral, Hepatic, and Adipose Insulin Sensitivity (IS) and Cardiometabolic Risk Factors in Youth across the Adiposity Spectrum

This paper was presented as a part of the session” Rising Risks, Real Solutions—Tackling Childhood Type 2 Diabetes and Obesity” on June 22nd, 2025, at

CagriSema Demonstrates Dual Benefit in Obesity and Type 2 Diabetes

This paper was presented as a part of the session” Late Breaking Poster/ Trials Sessions “on June 22nd, 2025, at the 85th ADA Scientific Sessions

Higher Static Phase Insulin Secretory Rate Compensates for Lower Insulin Sensitivity in South Asian Youth—The Charisma Study

This paper was presented as a part of the session” Rising Risks, Real Solutions—Tackling Childhood Type 2 Diabetes and Obesity” on June 22nd, 2025, at

STRIDE: Semaglutide Reduces Progression of PAD by 54% in Type 2 Diabetes

This paper was presented as a part of the session” Late Breaking Poster/ Trials Sessions “on June 22nd, 2025, at the 85th ADA Scientific Sessions

The Broader Impact of Sotagliflozin–Metaanalysis of Its Efficacy in Diabetes Management, Cardiovascular Risk Reduction, and Renal Outcome

This paper was presented as a part of the session “Dropping Cost and Complications—CVD Risk and DM—SGLT2s and GLPs for CVD” on June 22nd, 2025,

Association between Triglyceride, Glucose, and Body Mass Index and Long-Term Adverse Outcomes in Heart Failure Patients with Coronary Heart Disease

This paper was presented as a part of the session “The Tidal Wave Is Coming—Heart Failure Diagnosis, Prevention, and Treatment in Patients with Type 2

Comparative Evaluation of Current Therapeutic Agents for Heart Failure with Preserved Ejection Fraction (HFpEF)–A Systematic Review and Network Meta-analysis

This paper was presented as a part of the session “The Tidal Wave Is Coming—Heart Failure Diagnosis, Prevention, and Treatment in Patients with Type 2

Diabetes and Peripheral Artery Disease— Evolving Role of GLP-1 RA and New Insights from the STRIDE Trial

This session was presented on June 21st, 2025, at the 85th ADA Scientific Sessions being held in Chicago, IL. A major international clinical trial has